Muhammad Zaeem Noman
Overview
Explore the profile of Muhammad Zaeem Noman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
4121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu Y, Bogdan M, Noman M, Parpal S, Bartolini E, Van Moer K, et al.
Mol Oncol
. 2024 Mar;
18(8):1904-1922.
PMID: 38506049
An immunosuppressive tumor microenvironment promotes tumor growth and is one of the main factors limiting the response to cancer immunotherapy. We have previously reported that inhibition of vacuolar protein sorting...
2.
Noman M, Bocci I, Karam M, Van Moer K, Bosseler M, Kumar A, et al.
Front Immunol
. 2022 Dec;
13:980704.
PMID: 36458012
Harmine is a dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor that displays a number of biological and pharmacological properties. Also referred to as ACB1801 molecule, we have previously reported that harmine...
3.
Hasmim M, Xiao M, Van Moer K, Kumar A, Oniga A, Mittelbronn M, et al.
Front Immunol
. 2022 Sep;
13:982821.
PMID: 36159844
Triple-negative subtype of breast cancer (TNBC) is hallmarked by frequent disease relapse and shows highest mortality rate. Although PD-1/PD-L1 immune checkpoint blockades have recently shown promising clinical benefits, the overall...
4.
Kiweler N, Delbrouck C, Pozdeev V, Neises L, Soriano-Baguet L, Eiden K, et al.
Nat Commun
. 2022 May;
13(1):2699.
PMID: 35577770
Metastasis is the most common cause of death in cancer patients. Canonical drugs target mainly the proliferative capacity of cancer cells, which leaves slow-proliferating, persistent cancer cells unaffected. Metabolic determinants...
5.
Messai Y, Noman M, Hasmim M, Janji B, Tittarelli A, Boutet M, et al.
Cancer Res
. 2022 Apr;
82(8):1671.
PMID: 35425966
No abstract available.
6.
Lequeux A, Noman M, Xiao M, Van Moer K, Hasmim M, Benoit A, et al.
Oncogene
. 2021 Jun;
40(28):4725-4735.
PMID: 34155342
Hypoxia is a key factor responsible for the failure of therapeutic response in most solid tumors and promotes the acquisition of tumor resistance to various antitumor immune effectors. Reshaping the...
7.
Xiao M, Hasmim M, Lequeux A, Van Moer K, Tan T, Gilles C, et al.
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33803139
CMTM6 is a critical regulator of cell surface expression of PD-L1 in tumor cells, but little is known about the transcriptional regulation of CMTM6. Here we report that the expression...
8.
Chevigne A, Janji B, Meyrath M, Reynders N, DUonnolo G, Uchanski T, et al.
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33801414
Atypical chemokine receptors (ACKRs) are important regulators of chemokine functions. Among them, the atypical chemokine receptor ACKR2 (also known as D6) has long been considered as a scavenger of inflammatory...
9.
Xiao M, Benoit A, Hasmim M, Duhem C, Vogin G, Berchem G, et al.
Front Oncol
. 2021 Mar;
11:626309.
PMID: 33718194
Autophagy is a highly regulated multi-step process that occurs at the basal level in almost all cells. Although the deregulation of the autophagy process has been described in several pathologies,...
10.
Schlapfer A, Auclair C, Janji B, Karam M, Noman M
Chimia (Aarau)
. 2020 Oct;
74(10):771-775.
PMID: 33115558
AC BioScience is a Swiss biotech company based at the EPFL Innovation Park and Biopôle, dedicated to developing groundbreaking therapies to fight a range of cancers and infectious diseases. We...